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STUDY QUESTION: Does chemotherapy exposure (with or without alkylating agents) or primary diagnosis affect spermatogonial quantity
in human prepubertal testicular tissue?
SUMMARY ANSWER: Spermatogonial quantity is signiﬁcantly reduced in testes of prepubertal boys treated with alkylating agent therapies
or with hydroxyurea for sickle cell disease.
WHAT IS KNOWN ALREADY: Cryopreservation of spermatogonial stem cells, followed by transplantation into the testis after treat-
ment, is a proposed clinical option for fertility restoration in children. The key clinical consideration behind this approach is a sufﬁcient quan-
tity of healthy cryopreserved spermatogonia. However, since most boys with malignancies start therapy with agents that are not potentially
sterilizing, they will have already received some chemotherapy before testicular tissue cryopreservation is considered.
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STUDY DESIGN, SIZE, DURATION: We examined histological sections of prepubertal testicular tissue to elucidate whether chemo-
therapy exposure or primary diagnosis affects spermatogonial quantity. Quantity of spermatogonia per transverse tubular cross-section (S/T)
was assessed in relation to treatment characteristics and normative reference values in histological sections of parafﬁn embedded testicular
tissue samples collected from 32 consecutive boy patients (aged 6.3 ± 3.8 [mean ± SD] years) between 2014 and 2017, as part of the
NORDFERTIL study, and in 14 control samples (from boys aged 5.6 ± 5.0 [mean ± SD] years) from an internal biobank.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Prepubertal boys in Sweden, Finland and Iceland who were facing treatments
associated with a very high risk of infertility, were offered the experimental procedure of testicular cryopreservation. Exclusion criteria were tes-
ticular volumes >10ml and high bleeding or infection risk. There were 18 patients with a diagnosis of malignancy and 14 patients a non-
malignant diagnosis. While 20 patients had the testicular biopsy performed 1–45 days after chemotherapy, 12 patients had not received any
chemotherapy. In addition, 14 testicular tissue samples of patients with no reported testicular pathology, obtained from the internal biobank of
the Department of Pathology at Karolinska University Hospital, were included as control samples in addition to reference values obtained from a
recently published meta-analysis. The quantity of spermatogonia was assessed by both morphological and immunohistochemical analysis.
MAIN RESULTS AND THE ROLE OF CHANCE: The main ﬁnding was a signiﬁcant reduction in spermatogonial cell counts in boys trea-
ted with alkylating agents or with hydroxyurea for sickle cell disease. The mean S/T values in boys exposed to alkylating agents (0.2 ± 0.3,
n = 6) or in boys with sickle cell disease and exposed to hydroxyurea (0.3 ± 0.6, n = 6) were signiﬁcantly lower (P = 0.003 and P = 0.008,
respectively) than in a group exposed to non-alkylating agents or in biobank control samples (1.7 ± 1.0, n = 8 and 4.1 ± 4.6, n = 14, respect-
ively). The mean S/T values of the testicular tissue samples included in the biobank control group and the patient group exposed to non-
alkylating agents were within recently published normative reference values.
LIMITATIONS, REASONS FOR CAUTION: Normal testicular tissue samples included in this study were obtained from the internal
biobank of Karolinska University Hospital. Samples were considered normal and included in the study if no testicular pathology was reported
in the analysed samples. However, detailed information regarding previous medical treatments and testicular volumes of patients included in
this biobank were not available.
WIDER IMPLICATIONS OF THE FINDINGS: This study summarizes, for the ﬁrst time, spermatogonial quantity in a prepubertal
patient cohort just before and after potentially sterilizing treatments. Boys facing cancer and cytotoxic therapies are regarded as the major
group who will beneﬁt from novel fertility preservation techniques. There are no previous reports correlating spermatogonial quantity to
cumulative exposure to alkylating agents and anthracyclines (non-alkylating agents) and no information about the timing of cytotoxic expo-
sures among this particular patient cohort. For prepubertal boys in whom fertility preservation is indicated, testicular tissue should be
obtained before initiation of chemotherapy with alkylating agents, whilst for those with sickle cell disease and treated with hydroxyurea, this
approach to fertility preservation may not be feasible.
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Introduction
Prepubertal boys treated with conditioning therapies for hematopoietic
stem cell transplantation (HSCT) or testicular radiotherapy are known to be
at very high risk of fertility impairment (Stukenborg et al., 2018). Fertility
preservation strategies for these boys primarily consist of cryopreservation
of testicular tissue followed by auto-transplantation of spermatogonial stem
cells (SSCs), tissue grafting or in-vitro maturation (Jahnukainen et al., 2015;
Picton et al., 2015; Dalle et al., 2017; McCracken and Nahata, 2017).
However, no pregnancies have been so far reported with sperm obtained
from these experimental strategies using immature testicular tissue (Picton
et al., 2015). The collection of testicular tissue is considered as an invasive
procedure, and therefore the inclusion criteria for participating in testicular
tissue cryopreservation programmes should be restricted to patients at the
highest risk of infertility (i.e. those receiving total body irradiation or chemo-
therapy conditioning before HSCT, radiation applied to the testes or treat-
ment with high dose alkylating agents) (Anderson et al., 2015).
Only a small proportion of boys with malignancies will start therapy
with agents that carry a high risk of infertility and therefore most boys
are not offered cryopreservation initially. However, they may become
eligible by fulﬁlling selection criteria, if further treatment is required
due to poor response to therapy or relapse (Jahnukainen et al., 2015).
This means that the majority of patients eligible for fertility preserva-
tion have already received chemotherapy before testicular tissue cryo-
preservation is considered (Jahnukainen et al., 2015; Balduzzi et al.,
2017). The previous studies reporting spermatogonial quantities in
paediatric cohorts have mainly focused on archived historical material
(Van Saen et al., 2015; Poganitsch-Korhonen et al., 2017) or report
1678 Stukenborg et al.
heterogonous material combining samples from boys with cancer and
samples from boys with primary testicular pathology including
Klinefelter syndrome and cryptorchidism (Heckmann et al., 2018).
Today, various research teams have reported their experience of
conducting fertility preservation programmes in prepubertal boys. This
includes reports on sampling for cryobanking, patient and parent atti-
tudes, and clinical decision factors for the parents and child (Anderson
et al., 2015; Picton et al., 2015; Van Saen et al., 2015; Heckmann et al.,
2018). However, to the best of our knowledge, there are no previous
reports correlating spermatogonial quantity to cumulative exposure to
cytotoxic drugs in a prepubertal patient cohort prior to potentially
sterilizing oncological treatments. Therefore, information regarding the
fertility status of testicular tissue obtained from prepubertal and puber-
tal boys subjected to gonadotoxic treatments before the time of
biopsy is still very limited.
Regarding patients with non-malignant conditions who may be sub-
jected to gonadotoxic treatments prior to biopsy, sickle cell disease
(SCD) represents one of the largest groups worldwide in which allo-
geneic hematopoietic stem cell transplantation may be indicated.
Patients with SCD suffer from vaso-occlusion that causes tissue hyp-
oxia and organ damage. In order to reduce the incidence of vaso-
occlusive crises, patients receive the antineoplastic agent hydroxyurea
which prevents DNA synthesis through the inhibition of ribonucleo-
side diphosphate reductase. Therefore, these patients with SCD often
receive treatment with hydroxyurea, and so a large proportion of boys
with SCD facing HSCT and eligible for fertility preservation will have
already received this chemotherapy before testicular tissue cryo-
preservation is offered (Jahnukainen et al., 2015; Balduzzi et al., 2017).
Hydroxyurea is known to decrease sperm quality in adult males
(Berthaut et al., 2008); however, its effects on immature testes have
not been described to date.
Fertility preservation in relapsed leukaemia and for patients with
SCD demonstrates that, in clinical settings, it may be difﬁcult to
totally avoid exposure to cytotoxic therapies prior to testicular tis-
sue cryopreservation. Therefore, information regarding the effect
of previous exposure to potentially gonadotoxic treatment on
spermatogonial quantity are required. Spermatogonial quantity per
tubular cross section (S/T) has been shown to correspond to
secretion of inhibin b, testosterone, luteinizing and follicle-
stimulating hormone, and recently testicular reference values for
S/T in human testes throughout healthy prepuberty have been
established (Masliukaite et al., 2016). In order to optimize patient
selection and subsequent clinical cryobanking, these reference
values were used to evaluate the effects of primary diagnosis and
initial cancer treatment on spermatogonial quantity in the pre-
pubertal testicular tissue collected for fertility preservation prior to
potentially sterilizing therapy.
Materials andmethods
Ethical approval
Ethical approval was obtained from the ethics Board of Karolinska Institutet
and the Regional Ethics Board in Stockholm (Dnr 2013-2129-31-3, Dnr
2014/267-31/4 and Bio Bank approval BbK-01184), the National Ethics
Board of Iceland, Reykjavik (VSN 15-002) and the Ethics Board of the
University of Helsinki (426/13/03/03/2015).
Patients and treatments
Prepubertal boys in Sweden, Finland and Iceland, who were facing treat-
ments associated with a very high risk of infertility (allogeneic or autolo-
gous HSCT or testicular radiotherapy) (Skinner et al., 2017), were offered
the experimental procedure of testicular cryopreservation. Exclusion cri-
teria were a high bleeding and/or infection risk. Inclusion criteria for the
study were very high risk of therapy-related infertility and a testicular vol-
ume below 10 ml (measured by orchidometer). The parents and, where
appropriate, the patient received verbal and written information about the
research project and gave their written informed consent. Clinical treat-
ment characteristics were recorded and pseudo-anonymised for entry into
the research database. Patients underwent unilateral open testicular
biopsy where less than 20% of the testicular volume of one testis was
sampled. Two-thirds was cryopreserved according to a protocol published
by Keros and colleagues for clinical fertility preservation (Keros et al., 2007)
and the remaining third was anonymized and transported to the
NORDFERTIL research laboratory at Karolinska Institutet. Of 32 boys were
enroled in the study from 2014 until 2017, 18 had a diagnosis of malignancy
and 14 had a non-malignant diagnosis (Supplementary Table SI), while 20
had a testicular biopsy performed 1–45 days after a previous dose of
chemotherapy. Alkylating agents were included in the therapeutic regimen
for six patients while six SCD patients were treated with hydroxyurea, a
chemotherapy agent. Alkylating agent exposures were calculated as mean
cumulative cyclophosphamide equivalent doses (CEDs) (Green et al., 2014)
and cumulative doxorubicin were calculated as isotoxic dose equivalents
(DIE) using conversion factor 1 for doxorubicin and 0.833 for daunorubicin.
In addition, the daily dose of hydroxyurea (HU), the time since last exposure
and as the time period between the start of chemotherapy and the biopsy
are presented (Supplementary Table SI and Table I).
In addition, 14 testicular samples (5.6 ± 5.0 [mean ± SD] years of age)
without testicular pathology from the biobank of the Department of
Pathology, Karolinska University Hospital served as controls.
Tissue processing and histological analyses
Testicular biopsy samples from 46 boys (32 patients and 14 control tes-
ticular tissue samples) were ﬁxed in formalin, 4% in phosphate buffered
saline and afterwards embedded in parafﬁn. Section (5 μm thick) were
obtained and non-consecutive sections, randomly selected, were stained
with periodic acid-Schiff (PAS) or immunostained with an antibody against
a germ cell marker (DDX4) as previously described (Alves-Lopes et al.,
2017). In brief, following antigen retrieval, sections were blocked with a
blocking buffer containing normal donkey serum 10% (NDS; 017-00-121,
Jackson Immuno Research, PA, USA) and 1.5% bovine serum albumin
(BSA) in Tris-buffered saline (TBS) at room temperature for one hour.
Sections were incubated at 4°C overnight with mouse monoclonal anti-
DDX4 primary antibody (ab27591, Abcam, Cambridge, UK; ﬁnal concen-
tration 1.7 μg/ml) and rabbit polyclonal anti-SOX9 (AB5535, Merck
Millipore, Frankfurt, Germany, ﬁnal concentration 4.3 μg/ml) diluted in
blocking buffer. For negative controls, primary antibodies were replaced
by mouse IgGs (sc-2025, Santa Cruz Biotechnology, Dallas, TX, USA; ﬁnal
concentration 4 μg/ml) and rabbit IgGs (ab 27478, Abcam, Cambridge,
UK; ﬁnal concentration 2 μg/ml) diluted in blocking buffer (TBS/NDS/
BSA). Sections were washed in TBS three times for 5 min each, followed
by incubation for 1 h at room temperature with Alexa 488 donkey anti-
mouse (715546150, Thermo Fisher, Waltham, USA; ﬁnal concentration
3 μg/ml) and Cy3-conjugated donkey anti-rabbit (11483299, Thermo
Fisher; ﬁnal concentration 3 μg/ml) secondary antibodies diluted in block-
ing buffer. Sections were washed in TBS three times for 5 min each and
mounted in VECTASHIELD mounting medium with DAPI (H-1500,
Vector, CA, USA),
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PAS kit (101646, Merck, Darmstadt, Germany) was used to stain the sec-
tions according to the manufacturer’s protocol. Brieﬂy, after re-hydration, sec-
tions were washed in distilled water twice for 5min each and incubated in
periodic acid for 5min. This was followed by thorough washing under running
tap water and then twice in distilled water for 5min each. Afterwards, sections
were incubated in Schiff’s reagent for 15min and washed thoroughly again
under running tap water and twice in distilled water for 5min each. Then, sam-
ples were counter-stained with hematoxylin (Mayer’s Hemalaun solution,
1092491000, Merck) for 2min and washed in running tap water for 2min,
dehydrated and ﬁnally mounted in Entellan® new (1079610100, Merck).
Blind analysis of spermatogonial numbers per round tubular cross-section
(S/T) was performed by an experienced examiner using a bright-ﬁeld micro-
scope (Eclipse E800, Nikon; Japan). All or, at least 25, round tubular cross-
sections per sample were evaluated to achieve result validity (Stadtler and
Mausle, 1971). The spermatogonia were identiﬁed in non-consecutive tissue sec-
tions from each patient on the basis of their morphology (size, shape and loca-
tion) (Paniagua and Nistal, 1984) in PAS stained sections as well as on the basis
of their DDX4 expression (Supplementary Fig. S1). There was a minimum dis-
tance of at least 15 μm between sections used for each staining method
from the same patient sample to avoid the evaluation of identical cells by the
two staining methods. For spermatogonial quantiﬁcation, a signiﬁcant correl-
ation (r = 0.828, P < 0.0001; Supplementary Fig. S2) existed between
morphology and immunostaining, and therefore only results from DDX4-
staining are presented.
Statistical analysis
Results are reported as mean ± standard deviation (SD) and range. Student’s
unpaired t test (normally distributed variables), the Mann–Whitney U test (non-
normally distributed variables) and Pearson correlation coefﬁcient (r) were used
as appropriate to determine the relationships between spermatogonial quantity,
age and treatment characteristics. Analyses were performed using IBM SPSS
Statistics V23.0 software (IBMCorporation, Armonk, NY, USA).
Results
Quantity of spermatogonia per seminiferous
tubule in immature testes of boys
Mean S/T in samples from cancer patients exposed to non-alkylating
agents (1.7 ± 1.0, n = 8) and biobank controls (4.1 ± 4.6, n = 14) did
not exhibit signiﬁcant differences in S/T numbers. Both groups were
within the 95% conﬁdence intervals of normative reference values
(Masliukaite et al., 2016) (Table I, Fig. 1). In contrast, samples from
cancer patients exposed to alkylating agents, exhibited a lower mean
S/T value (0.2 ± 0.3, n = 6) compared with samples from patients
treated with non-alkylating agents (P = 0.003) or biobank controls
(P < 0.001) (Table I, Fig. 1). Spermatogonial quantity correlated with
cumulative exposure to alkylating agents (r = −0.579, P = 0.024), but
not to anthracyclines (r = −0.133, P = 0.637) or patient age (r =
0.398, P = 0.142). Among ﬁve boys exposed to CED close to or over
4000 mg/m2, S/T values were close to zero (Supplementary Table SI).
In samples from six patients with SCD, a lower mean S/T value (0.3 ±
0.6, n = 6) was found compared with samples from biobank controls
(P = 0.003) (Table I, Fig. 1). Five boys with SCD aged 4–7 and 13 years
had a totally depleted spermatogonial pool, while the remaining 11.5
year old boy had low spermatogonial quantity compared to normal
values present in the control material (Fig. 1, Supplementary Table SI).
All boys with SCD had received hydroxyurea.
The patients with malignant or non-malignant diagnoses and who were
not previously exposed to chemotherapy showed marked variation in
their spermatogonial quantity (Fig. 1, Supplementary Table SI). Five
patients with known single gene mutations (three thalassaemia majors,
one Fanconi anaemia and one immunodeﬁciency caused by variant of
FOXP3-gene) showed reduced spermatogonial quantity (0.4 ± 0.5)
compared to controls (P = 0.006) (Supplementary Table SI).
Discussion
Although, fertility preservation in boys before or after gonadotoxic
medical treatments is currently a hot topic in the ﬁeld of reproductive
medicine/biology and paediatric oncology/haematology, there are no
previous reports that correlate spermatogonial quantity with cumula-
tive exposure to alkylating agents and anthracyclines or to information
about timing of cytotoxic exposures among this particular patient
cohort. This study describes, for the ﬁrst time, effects of previous cyto-
toxic therapy on spermatogonial quantity in a prepubertal patient
cohort just before potentially sterilizing oncological treatments and
.............................................................................................
.............................................................................................................................................................................................
Table I Descriptive statistics of testicular histology and treatment exposures for 32 boys who underwent testicular
biopsy for fertility preservation and for 14 control samples from Karolinska Institutet’s internal biobank.
Parameter Chemotherapy
Controls
(biobank)
No
chemotherapy
Hydroxyurea for SCD Non-alkylating agents Alkylating agents
(n = 14) (n = 12) (n = 6) (n = 8) (n = 6)
Age (y) 5.6 ± 5.0 4.9 ± 3.1 7.9 ± 3.6 6.6 ± 4.8 7.3 ± 3.7
Spermatogonia/cross-section 4.1 ± 4.6 0.8 ± 0.9* 0.3 ± 0.6*,## 1.7 ± 1.0 0.2 ± 0.3*,##
Proportion of SCO tubules (%) 40 ± 30 69 ± 21*,## 90 ± 17*,## 46 ± 18 89 ± 14*,##
Exposure to cyclophosphamide (g/m2) 0 0 0 0 5.1 ± 3.2
CED (g/m2) 0 0 0 0 5.5 ± 3.0
Cumulative anthracycline dose (mg/m2) 0 0 0 161 ± 166 249 ± 118
Hydroxyurea (mg/kg) 0 0 24.5 ± 2.7 0 0
Abbreviations: CED, cumulative cyclophosphamide equivalent dose; SCO, Sertoli cell-only; SCD, sickle cell disease.
*P < 0.05 when compared to value in control group, ##P < 0.05 when compared to value in group exposed to non-alkylating chemotherapy.
1680 Stukenborg et al.
fertility preservation. The main ﬁnding was that boys receiving alkylat-
ing agents and SCD patients receiving hydroxyurea had signiﬁcantly
depleted numbers of spermatogonia in their testicular tissue samples
compared to other patients exposed to non-alkylating agents or to
biobank controls.
In a recent retrospective study evaluating testicular tissue samples
obtained between 1979 and 1995 (Poganitsch-Korhonen et al., 2017),
a depletion of the spermatogonial pool was demonstrated after a CED
above 4000 mg/m2. Despite the limited number of samples, similar-
ities in quantity of spermatogonia per transverse tubular cross-section
(S/T) were observed in comparable patient groups between the two
studies. For non-alkylating exposed boys, mean SD values for S/T
were 1.7 ± 1.0 in this study, compared with 1.6 ± 0.8 in the previous
study (Poganitsch-Korhonen et al., 2017), whilst for boys exposed to
alkylating agents mean SD values for S/T were 0.2 ± 0.3 and 0.4 ±
0.5, respectively. Mean age across all groups in the two studies ranged
from 5.3 to 7.3 years. In the study of Poganitsch-Korhonen and collea-
gues, the number of spermatogonia was compared to reference values
obtained from a meta-analysis published in 2016 (Masliukaite et al.,
2016). The reference values summarized the quantity of spermato-
gonia in boys up to the age of 14 years. A decreasing number of
spermatogonia per seminiferous tubular cross section from 2.5 to 1.2
was described from birth to three years of age, followed by an increase
up to 2.6 spermatogonia per tubular cross section at the age of six-to-
seven and a plateau until the age of eleven. At the onset of puberty an
incline up to seven spermatogonia per tubular cross section could be
observed (Masliukaite et al., 2016).
Our observations on spermatogonia quantity in boys exposed to
treatment protocols used between 2014 and 2017 are in concordance
with our previous study on tissue samples of boys treated between
1978 and 1995 (Poganitsch-Korhonen et al., 2017) as well as previous
reports showing that leukaemia therapy in childhood involving alkylat-
ing agents results in depletion of the spermatogonial pool and
decreased fertility after cumulative CEDs greater than 4000 mg/m2
(Nurmio et al., 2009; Green et al., 2014). Therefore, these results
strongly suggest that tissue samples containing SSCs for fertility preser-
vation should be collected before initiating alkylating agent therapies.
The second main outcome of this study is that spermatogonial quan-
tity is signiﬁcantly reduced in testes of prepubertal boys treated with
hydroxyurea for SCD. Our ﬁndings demonstrated a highly signiﬁcant
reduction, or in some cases total depletion, of spermatogonia in SCD
patients treated with hydroxyurea. A previous case study reported a
29 year old SCD patient with a normal sperm count (88 × 106 sperm/
ml) prior to treatment, who became azoospermic one month after
commencing hydroxyurea (Garozzo et al., 2000). Ten months after his
hydroxyurea treatment was discontinued, his sperm count had par-
tially recovered (35 × 106 sperm/ml), suggesting a reversible effect on
sperm counts in adult men receiving hydroxyurea (Garozzo et al.,
2000). This study, was followed by a retrospective study investigating
the inﬂuence of clinically relevant hydroxyurea (20–30 mg/kg body
weight/day) on fertility in adult male SCD patients (Berthaut et al.,
2008). This study by Berthaut and colleagues demonstrated a negative
effect of hydroxyurea on semen parameters during treatment, which
persisted in some of the patients after cessation of treatment
(Berthaut, et al. 2008). Another study, addressing gonadal function in
children with SCD (2.25–14.16 years of age) and not exposed to
hydroxyurea, revealed spontaneous puberty in boys after HSCT
(Brachet et al., 2004). However, boys included in this study had smaller
Figure 1 Spermatogonial numbers per tubular cross-section (S/T) of testicular tissues obtained for fertility preservation from boys with sickle cell
disease receiving hydroxyurea (black circles), those exposed to alkylating (black squares) or non-alkylating chemotherapy (white squares), and those
not exposed to previous treatment (white dots) as well as biobank controls (light grey dots). Each dot or square represents the mean spermatogonial
number for an individual patient. The Y-axis represents patient age in years. Data are plotted on a meta-regression ﬁt line of reference values for
spermatogonia per tubular cross section (S/T) throughout healthy prepuberty, as previously reported (Masliukaite et al., 2016).
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testes and increased serum levels of follicle-stimulating hormone, sug-
gesting an impaired germinal epithelium, which may have resulted from
HSCT (Brachet et al., 2004). One previous study has evaluated the
quality of testicular tissue from SCD boys and observed depletion of
spermatogonia in two out of ﬁve boys aged between 5 and 15 years
(Van Saen et al., 2015). SCD itself can decrease spermatogonial quan-
tity, since vaso-occlusions and chronic anaemia are associated with
decreased pubertal testicular growth (Martins et al., 2015). The SCD
boys in the present study were all exposed to hydroxyurea
(20–25 mg/kg) which is an S-phase-speciﬁc cytotoxic and antineoplas-
tic agent (Wang et al., 2011). Hydroxyurea is reported to suppress
spermatogenesis in adult men with SCD (DeBaun, 2014). The present
ﬁndings suggest that it may also cause spermatogonial loss before
puberty, although the relative contribution of the disease or the treat-
ment remains to be established. In the present study detailed identiﬁ-
cation of exact treatment related effects could not be separated from
the direct effects of the SCD itself. Therefore, further studies in boys
with SCD comparing those exposed to hydroxyurea with non-
exposed SCD patients are needed before ﬁnal recommendations
regarding fertility preservation in this patient population can be given.
In addition to reduced numbers of spermatogonia in SCD patients
treated with hydroxyurea, testicular tissue samples obtained from
boys diagnosed with other single gene mutations (thalassaemia majors,
Fanconi anaemia and immunodeﬁciency caused by variant of FOXP3-
gene) showed a reduced quantity of spermatogonia. These observa-
tions suggest that genetic abnormalities in haematological diseases may
also be associated with reduced numbers of spermatogonia in pre-
pubertal testes. The spermatogonial quantity in these patients prior to
the initiation of any chemotherapy may reﬂect the effects of genetic
diagnosis and constitutional disease on testicular development and fer-
tility potential.
However, a limitation of our study was that the internal biobank did
not provide information about the medical treatment of subjects prior to
tissue sampling. This could affect the validity of this population as a con-
trol group. Therefore, in order to validate the biobank tissues as appro-
priate control material, we compared the samples to the normative
reference values obtained from a meta-analysis of six independent stud-
ies (Masliukaite et al., 2016). This demonstrated that the biobank control
material was within the previously published normative reference values.
In conclusion, we have demonstrated that spermatogonial quantity
in clinical fertility preservation material collected after cancer therapy
does not differ from biobank control samples and remains within nor-
mative reference values for prepubertal boys who did not receive
alkylating agents. However, for those boys receiving alkylating agents
and SCD patients receiving hydroxyurea there is a signiﬁcant depletion
of the spermatogonial pool when compared to the biobank control
samples. Therefore, in order to collect sufﬁcient amounts of sperm-
atogonial stem cells for intended fertility preservation, a testicular
biopsy sample should be acquired prior to exposure to alkylating
agents. Boys with SCD and their parents should be aware of the pre-
disposition for reduced spermatogonial quantity and decreased poten-
tial for successful fertility preservation as a result of the disease and/or
the exposure to hydroxyurea therapy.
Supplementary data
Supplementary data are available at Human Reproduction online.
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